Financial reports
10-K/A
2023 FY
Annual report (amended)
22 Apr 24
10-K/A
2023 FY
Annual report (amended)
23 Feb 24
10-K
2023 FY
Annual report
22 Feb 24
10-Q
2023 Q3
Quarterly report
7 Nov 23
ARS
2022 FY
Annual report to shareholders
15 Aug 23
10-Q
2023 Q2
Quarterly report
1 Aug 23
10-Q
2023 Q1
Quarterly report
15 May 23
10-K/A
2022 FY
Annual report (amended)
20 Apr 23
10-K
2022 FY
Annual report
8 Mar 23
10-Q
2022 Q3
Quarterly report
9 Nov 22
Current reports
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
12 Apr 24
8-K
Other Events
27 Feb 24
8-K
Submission of Matters to a Vote of Security Holders
28 Sep 23
8-K
Minerva Neurosciences Announces $20 Million in Private Placement Priced at a Premium to Market
28 Jun 23
8-K
Other Events
20 Jun 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
2 Jun 23
8-K
Departure of Directors or Certain Officers
5 May 23
8-K
Minerva Neurosciences Announces the NDA Filing for Roluperidone for the Treatment of Negative Symptoms in Schizophrenia
1 May 23
8-K
Minerva Neurosciences Announces Update on its New Drug Application (NDA) for Roluperidone for the Treatment of Negative Symptoms in Schizophrenia
28 Dec 22
8-K
Departure of Directors or Certain Officers
16 Dec 22
Registration and prospectus
424B3
Prospectus supplement
9 Aug 23
S-3
Shelf registration
4 Aug 23
D
$20.00 mm in equity / options / securities to be acquired, 4 investors
3 Jul 23
S-3
Shelf registration
14 Sep 22
SC TO-I/A
Issuer tender offer statement (amended)
9 Aug 21
SC TO-I/A
Issuer tender offer statement (amended)
2 Aug 21
SC TO-I
Issuer tender offer statement
6 Jul 21
S-8
Registration of securities for employees
10 Aug 20
RW
Registration withdrawal request
11 Apr 19
S-3
Shelf registration
10 Aug 18
Proxies
DEFA14A
Additional proxy soliciting materials
15 Aug 23
DEF 14A
Definitive proxy
15 Aug 23
DEFA14A
Additional proxy soliciting materials
26 Apr 22
DEF 14A
Definitive proxy
26 Apr 22
PRE 14A
Preliminary proxy
14 Apr 22
DEFA14A
Additional proxy soliciting materials
30 Apr 21
DEF 14A
Definitive proxy
30 Apr 21
PRE 14A
Preliminary proxy
20 Apr 21
DEFA14A
Additional proxy soliciting materials
28 Apr 20
DEF 14A
Definitive proxy
28 Apr 20
Other
EFFECT
Notice of effectiveness
10 Aug 23
CORRESP
Correspondence with SEC
7 Aug 23
UPLOAD
Letter from SEC
7 Aug 23
EFFECT
Notice of effectiveness
26 Sep 22
UPLOAD
Letter from SEC
21 Sep 22
CORRESP
Correspondence with SEC
21 Sep 22
UPLOAD
Letter from SEC
21 Sep 22
CORRESP
Correspondence with SEC
14 Sep 22
UPLOAD
Letter from SEC
12 Sep 22
EFFECT
Notice of effectiveness
24 Aug 18
Ownership